Diphenhydramine Hydrochloride


Pharmaceutical Associates, Inc.
Human Prescription Drug
NDC 0121-0978
Diphenhydramine Hydrochloride is a human prescription drug labeled by 'Pharmaceutical Associates, Inc.'. National Drug Code (NDC) number for Diphenhydramine Hydrochloride is 0121-0978. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Diphenhydramine Hydrochloride drug includes Diphenhydramine Hydrochloride - 25 mg/10mL . The currest status of Diphenhydramine Hydrochloride drug is Active.

Drug Information:

Drug NDC: 0121-0978
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Diphenhydramine Hydrochloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Diphenhydramine Hydrochloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Pharmaceutical Associates, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DIPHENHYDRAMINE HYDROCHLORIDE - 25 mg/10mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:ORAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 10 Feb, 1982
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 12 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA087513
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Pharmaceutical Associates, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1049906
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:TC2D6JAD40
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Histamine H1 Receptor Antagonists [MoA]
Histamine-1 Receptor Antagonist [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
0121-0978-0010 TRAY in 1 CASE (0121-0978-00) / 10 CUP, UNIT-DOSE in 1 TRAY / 10 mL in 1 CUP, UNIT-DOSE (0121-0978-10)10 Feb, 1982N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Diphenhydramine hydrochloride diphenhydramine hydrochloride alcohol anhydrous citric acid d&c red no. 33 fd&c red no. 40 water sodium citrate sucrose diphenhydramine hydrochloride diphenhydramine diphenhydramine hydrochloride diphenhydramine hydrochloride alcohol anhydrous citric acid d&c red no. 33 fd&c red no. 40 water sodium citrate sucrose diphenhydramine hydrochloride diphenhydramine

Drug Interactions:

Drug interactions diphenhydramine hydrochloride has additive effects with alcohol and other cns depressants (hypnotics, sedatives, tranquilizers, etc.). mao inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Indications and Usage:

Indications and usage diphenhydramine hydrochloride in the oral form is effective for the following indications: antihistaminic for allergic conjunctivitis due to foods; mild, uncomplicated allergic skin manifestations of urticaria and angioedema; amelioration of allergic reactions to blood or plasma; dermatographism; as therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. motion sickness for active and prophylactic treatment of motion sickness. antiparkinsonism for parkinsonism (including drug-induced) in the elderly unable to tolerate more potent agents; mild cases of parkinsonism (including drug-induced) in other age groups; in other cases of parkinsonism (including drug-induced) in combination with centrally acting anticholinergic agents. nighttime sleep-aid.

Warnings:

Warnings antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder-neck obstruction. use in pediatric patients in pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. as in adults, antihistamines may diminish mental alertness in pediatric patients. in the young pediatric patient, particularly, they may produce excitation. use in the elderly (approximately 60 years or older) antihistamines are most likely to cause dizziness, sedation, and hypotension in elderly patients.

General Precautions:

General diphenhydramine hydrochloride has an atropine-like action and therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. use with caution in patients with lower respiratory disease including asthma.

Dosage and Administration:

Dosage and administration dosage should be individualized according to the needs and the response of the patient. a single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. the duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. adults 25 to 50 mg three to four times daily. the nightime sleep aid dosage is 50 mg at bedtime. pediatric patients (over 20 lbs.) 12.5 to 25 mg three or four times daily. maximum daily dosage not to exceed 300 mg. for physicians who wish to calculate the dose on the basis of body weight or surface area, the recommended dosage is 5 mg/kg/24 hours or 150 mg/m2/24 hours. data are not available on the use of diphenhydramine hydrochloride as a nighttime sleep-aid in children under 12 years. the basis for determining the most effective dosage regimen will be the response of the patient to medication and the condition under treatment. in moti
on sickness, full dosage is recommended for prophylactic use, the first dose to be given 30 minutes before exposure to motion and similar doses before meals and upon retiring for the duration of exposure

Contraindications:

Contraindications use in neonates or premature infants this drug should not be used in neonates or premature infants. use in nursing mothers because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers. antihistamines are also contraindicated in the following conditions hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

Adverse Reactions:

Adverse reactions the most frequent adverse reactions are underscored. general: urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of the mouth, nose and throat. cardiovascular system: hypotension, headache, palpitations, tachycardia, extrasystoles. hematologic system: hemolytic anemia, thrombocytopenia, agranulocytosis. nervous system: sedation, sleepiness, dizziness, disturbed coordination , fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions. gi system: epigastric distress , anorexia, nausea, vomiting, diarrhea, constipation. gu system: urinary frequency, difficult urination, urinary retention, early menses. respiratory system: thickening of bronchial secretions , tightness of chest or throat and wheezing, nasal stuffiness. to report suspected adverse reactions, contact pharmaceutical as
sociates, inc. at 1-800-845-8210 of fda at 1-800-fda-1088 or www.fda.gov/medwatch.

Drug Interactions:

Drug interactions diphenhydramine hydrochloride has additive effects with alcohol and other cns depressants (hypnotics, sedatives, tranquilizers, etc.). mao inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Use in Pregnancy:

Pregnancy pregnancy category b reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Pediatric Use:

Pediatric use diphenhydramine hydrochloride should not be used in neonates and premature infants (see contraindications ). diphenhydramine hydrochloride may diminish mental alertness, or, in the young pediatric patient, cause excitation. overdosage may cause hallucinations, convulsions, or death (see warnings and overdosage ). see also dosage and administration section.

Geriatric Use:

Use in the elderly (approximately 60 years or older) antihistamines are most likely to cause dizziness, sedation, and hypotension in elderly patients.

Overdosage:

Overdosage antihistamine overdosage reactions may vary from central nervous system depression to stimulation. stimulation is particularly likely in pediatric patients. atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing and gastrointestinal symptoms may also occur. if vomiting has not occurred spontaneously , the patient should be induced to vomit. this is best done by having him drink a glass of water or milk after which he should be made to gag. precaution against aspiration must be taken, especially in infants and children. if vomiting is unsuccessful , gastric lavage is indicated within 3 hours after ingestion and even later if large amounts of milk or cream were given beforehand. isotonic or 1/2 isotonic saline is the lavage solution of choice. saline cathartics , as milk of magnesia, by osmosis draw water into the bowel and therefore are valuable for their action in rapid dilution of bowel content. stimulants should not be used. vasopressors may be used to treat hypotension.

Description:

Description diphenhydramine hydrochloride is an antihistamine drug having the chemical name 2-(diphenylmethoxy)-n,n -dimethylethylamine hydrochloride and has the molecular formula c 17 h 21 no•hci (molecular weight 291.82). it occurs as a white odorless, crystalline powder and is freely soluble in water and alcohol. the structural formula is as follows: each 5 ml contains 12.5 mg of diphenhydramine hydrochloride and alcohol 14% for oral administration. inactive ingredients: citric acid, d&c red no. 33, fd&c red no. 40, flavoring, purified water, sodium citrate, and sucrose. diphenhydramine chemical structure

Clinical Pharmacology:

Clinical pharmacology diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative effects. antihistamines appear to compete with histamine for cell receptor sites on effector cells. a single oral dose of diphenhydramine hydrochloride is quickly absorbed with maximum activity occurring in approximately one hour. the duration of activity following an average dose of diphenhydramine hydrochloride is from four to six hours. diphenhydramine is widely distributed throughout the body, including the cns. little, if any, is excreted unchanged in the urine; most appears as the degradation products of metabolic transformation in the liver, which are almost completely excreted within 24 hours.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.

How Supplied:

How supplied each 5 ml of diphenhydramine hydrochloride oral solution usp (clear purple/red liquid, cinnamon/anise flavor) contains 12.5 mg diphenhydramine hydrochloride with 14% alcohol and is supplied in the following oral dosage forms: ndc: 0121-0489-04: 118 ml (4 oz) bottle ndc 0121-0489-05: 5 ml unit dose cup ndc 0121-0489-00: case contains 100 unit dose cups of 5 ml (0121-0489-05) packaged in 10 trays of 10 unit dose cups each. ndc 0121-0978-10: 10 ml unit dose cup ndc 0121-0978-00: case contains 100 unit dose cups of 10 ml (0121-0978-10) packaged in 10 trays of 10 unit dose cups each.

Information for Patients:

Information for patients patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol. patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc.

Package Label Principal Display Panel:

Principal display panel - 5 ml unit dose cup label delivers 5 ml ndc 0121-0489-05 diphenhydramine hcl oral solution usp 12.5 mg/5 ml alcohol 14% package not child-resistant store at 20° to 25°c (68° to 77°f). [see usp controlled room temperature]. rx only pharmaceutical associates, inc. greenville, sc 29605 see insert 5 ml unit dose cup label

Principal display panel - 10 ml unit dose cup label delivers 10 ml ndc 0121-0978-10 diphenhydramine hcl oral solution usp 25 mg/10 ml alcohol 14% package not child-resistant store at 20° to 25°c (68° to 77°f). [see usp controlled room temperature]. rx only pharmaceutical associates, inc. greenville, sc 29605 see insert 10 ml unit dose cup label

Principal display panel - 118 ml (4 oz) bottle delivers 118 ml ndc 0121-0489-04 diphenhydramine hydrochloride oral solution, usp 12.5 mg/5 ml each 5 ml (teaspoonfull) contains: diphenhydramine hcl 12.5 mg alcohol 14% rx only 118 ml pharmaceutical associates, inc. greenville, sc 29605 www.paipharma.com x0489040719 image description


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.